A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
Clinical trial NCT02725567 · COMPLETED
Trial details
- NCT number
- NCT02725567
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-02
- Primary completion
- 2022-06-28
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.